Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10233671 | 0.86 | — | — | |
| SCHEMBL15996487 | 0.82 | ADORA2A (0.33) | KCNH2CYP11B1CYP11B2 | |
| SCHEMBL14416003 | 0.76 | MAPK13 (0.33) | KCNH2CYP11B1CYP11B2 | |
| SCHEMBL26773832 | 0.76 | IDO1 (0.48) | KCNH2 | |
| Hydrochloric Acid SCHEMBL25311465 | 0.74 | CYP11B1 (0.38) | CYP11B1CYP11B2 | |
| SCHEMBL27984850 | 0.74 | CYP11B1 (0.62) | CYP11B1CYP11B2 | |
| SCHEMBL178520 | 0.73 | — | — | |
| SCHEMBL17544717 | 0.73 | CPB1 (0.30) | — | |
| SCHEMBL21514091 | 0.73 | — | — | |
| SCHEMBL25311885 | 0.72 | CYP11B1 (0.48) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030207-A1 | LINEAR CYCLODEXTRIN COPOLYMERS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2018-02-01 | — | — | US | disclosed |
| US-20170049903-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2017-02-23 | — | — | US | disclosed |
| US-20150203634-A1 | LINEAR CYCLODEXTRIN COPOLYMERS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-07-23 | — | — | US | disclosed |
| US-20150050233-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150031753-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150025126-A1 | METHOD OF PREPARING A SUPRAMOLECULAR COMPLEX CONTAINING A THERAPEUTIC AGENT AND A MULTI-DIMENSIONAL POLYMER NETWORK | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-01-22 | — | — | US | disclosed |
| US-20130197210-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130184453-A1 | LINEAR CYCLODEXTRIN COPOLYMERS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-07-18 | — | — | US | disclosed |
| US-8277846-B2 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120172525-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20110256104-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110182864-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-07-28 | — | — | US | disclosed |
| US-7968123-B2 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-06-28 | — | — | US | disclosed |
| US-20110143944-A1 | LINEAR CYCLODEXTRIN COPOLYMERS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144190-A1 | METHOD OF PREPARING A SUPRAMOLECULAR COMPLEX CONTAINING A THERAPEUTIC AGENT AND A MULTI-DIMENSIONAL POLYMER NETWORK | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-06-16 | — | — | US | disclosed |
| US-7807198-B2 | Compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7375096-B1 | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-05-20 | — | — | US | disclosed |
| US-20070128167-A1 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-06-07 | — | — | US | disclosed |
| US-20070025952-A1 | Linear cyclodextrin copolymers | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-02-01 | — | — | US | disclosed |
| US-7166302-B2 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025126-A1 | METHOD OF PREPARING A SUPRAMOLECULAR COMPLEX CONTAINING A THERAPEUTIC AGENT AND A MULTI-DIMENSIONAL POLYMER NETWORK | PICALM, IMMT, PAICS | KCNH2 4467/4885CYP11B1 301/4885CYP11B2 250/4885 |
| US-20110143944-A1 | LINEAR CYCLODEXTRIN COPOLYMERS | DDOST, SI, PDIA6 | KCNH2 4400/4885CYP11B1 4/4885CYP11B2 5/4885 |
| US-20110256104-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | KCNH2 4653/4885CYP11B1 214/4885CYP11B2 194/4885 |
| US-20180030207-A1 | LINEAR CYCLODEXTRIN COPOLYMERS | DDOST, SI, PDIA6 | KCNH2 4400/4885CYP11B1 4/4885CYP11B2 5/4885 |
| US-20150031753-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | KCNH2 4653/4885CYP11B1 214/4885CYP11B2 194/4885 |
| US-20070025952-A1 | Linear cyclodextrin copolymers | DDOST, SI, PDIA6 | KCNH2 4400/4885CYP11B1 4/4885CYP11B2 5/4885 |
| US-20110182864-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | EXOSC5, EXOSC9, INTS6 | KCNH2 4540/4885CYP11B1 109/4885CYP11B2 98/4885 |
| US-20070128167-A1 | Complexing agents for compositions containing inclusion complexes | INTS6, EXOSC5, PCBP1 | KCNH2 4653/4885CYP11B1 214/4885CYP11B2 194/4885 |
| US-20150050233-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | EXOSC5, EXOSC9, INTS6 | KCNH2 4540/4885CYP11B1 109/4885CYP11B2 98/4885 |
| US-20170049903-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | KCNH2 4653/4885CYP11B1 214/4885CYP11B2 194/4885 |
| US-20110144190-A1 | METHOD OF PREPARING A SUPRAMOLECULAR COMPLEX CONTAINING A THERAPEUTIC AGENT AND A MULTI-DIMENSIONAL POLYMER NETWORK | PICALM, IMMT, PAICS | KCNH2 4467/4885CYP11B1 301/4885CYP11B2 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.